Your browser doesn't support javascript.
loading
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.
Vredevoogd, David W; Kuilman, Thomas; Ligtenberg, Maarten A; Boshuizen, Julia; Stecker, Kelly E; de Bruijn, Beaunelle; Krijgsman, Oscar; Huang, Xinyao; Kenski, Juliana C N; Lacroix, Ruben; Mezzadra, Riccardo; Gomez-Eerland, Raquel; Yildiz, Mete; Dagidir, Ilknur; Apriamashvili, Georgi; Zandhuis, Nordin; van der Noort, Vincent; Visser, Nils L; Blank, Christian U; Altelaar, Maarten; Schumacher, Ton N; Peeper, Daniel S.
Affiliation
  • Vredevoogd DW; Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
  • Kuilman T; Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
  • Ligtenberg MA; Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
  • Boshuizen J; Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
  • Stecker KE; Biomolecular Mass Spectrometry and Proteomics, Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH, Utrecht, the Netherlands.
  • de Bruijn B; Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
  • Krijgsman O; Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
  • Huang X; Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
  • Kenski JCN; Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
  • Lacroix R; Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
  • Mezzadra R; Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
  • Gomez-Eerland R; Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
  • Yildiz M; Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
  • Dagidir I; Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
  • Apriamashvili G; Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
  • Zandhuis N; Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
  • van der Noort V; Division of Statistics, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
  • Visser NL; Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
  • Blank CU; Division of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
  • Altelaar M; Proteomics Facility, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands; Biomolecular Mass Spectrometry and Proteomics, Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH, Utrecht, the Netherlan
  • Schumacher TN; Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
  • Peeper DS; Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands. Electronic address: d.peeper@nki.nl.
Cell ; 178(3): 585-599.e15, 2019 07 25.
Article in En | MEDLINE | ID: mdl-31303383
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Necrosis Factor-alpha / CD8-Positive T-Lymphocytes / Immunotherapy Limits: Animals / Humans / Male Language: En Journal: Cell Year: 2019 Document type: Article Affiliation country: Países Bajos Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Necrosis Factor-alpha / CD8-Positive T-Lymphocytes / Immunotherapy Limits: Animals / Humans / Male Language: En Journal: Cell Year: 2019 Document type: Article Affiliation country: Países Bajos Country of publication: Estados Unidos